New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice - 29/08/11
Plan
Disclosure: Dr Callen has been an investigator on a study of etanercept for psoriatic arthritis and has received honoraria either directly or indirectly from Amgen (formerly Immunex), Genentech, Biogen, Centocor, Roche, Novartis, Doak Dermatologics, 3M, and Dermik. He has also served as a consultant for Biogen, Amgen (formerly Immunex), Doak Dermatologics, ICN, 3M, and Centocor. He is the Chair of the Ad Hoc Task Force: Psoriasis Education Initiative of the American Academy of Dermatology and was the Chair of the Psoriasis Therapies Educational Summit that was held in Louisville, Ky on November 2-3, 2002. |
Vol 49 - N° 2
P. 351-356 - août 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?